We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Roche has signed up for access to Vividion Therapeutics' proteomics screening platform and proprietary small molecule library to target E3 ligases and a range of oncology and immunology therapeutic targets.
Roche has signed an exclusive worldwide option and licence agreement with US-based biotechnology firm Vividion Therapeutics to discover and develop small molecules for various therapeutic targets.